Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Lord why didn't I buy back 2 months ago?
Nice summer rally here!
BTD baby!!! This board needs to seriously wake up!
Abeona Therapeutics Receives Guidance from FDA to Commence Pivotal Phase 3 for EB-101 Gene Therapy for Patients with Epidermolysis Bullosa
Tue July 18, 2017 8:05 AM
- Pivotal Phase 3 clinical trial is planned to commence in early 2018
- EB-101 gene therapy for patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) has demonstrated promising efficacy and safety in the Phase 1/2 clinical trial
EB-101 has received Orphan Drug and Rare Pediatric Disease Designations in the USA and Orphan Drug Designation in the EU
NEW YORK and CLEVELAND, July 18, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced today guidance from a recent Type-C meeting with the FDA which has recommended accelerating the EB-101 program into a pivotal Phase 3 trial. The Company continues to engage the FDA on the final Phase 3 clinical trial design, planned to commence early 2018, and will provide an update on the program in the coming months.
“The FDA guidance is an important milestone in our clinical development plan for EB-101, and we are pleased to be moving forward into a registrational Phase 3 clinical study in 2018. Abeona is committed to advancing innovative gene therapies that address the unmet needs of patients suffering with dystrophic epidermolysis bullosa, a devastating rare skin disease. We are grateful that the FDA has recognized EB-101 as a rare disease product that addresses the underlying disease pathology to offer significant therapeutic benefit for RDEB patients, and we look forward to the collective work ahead in advancing this therapy,” stated Timothy J. Miller, Ph.D., President and CEO of Abeona Therapeutics Inc.
Abeona’s EB-101 product is an autologous, ex-vivo gene therapy in which the COL7A1 gene is inserted into a patient’s own skin cells (keratinocytes) for the treatment of the underlying disease in Recessive Dystrophic Epidermolysis Bullosa. The EB-101 program has been granted Orphan Drug and Rare Pediatric Disease Designations from the US Food and Drug Administration (FDA) and Orphan Drug Designation from the European Medicines Agency (EMA).
“EB Research Partnership (EBRP), along with EB Medical Research Foundation, are honored to have helped support EB-101 development by the dedicated researchers at Stanford University. Their tireless efforts in combination with Abeona’s leadership is driving real progress in the RDEB patient community. EBRP is encouraged by clinical results to date and looks forward to realizing the promise of EB-101 in addressing the devastating effects on RDEB patients’ quality of life and disease burden,” stated Alexander Silver, co-founder and chairman EB Research Partnership.
About EB-101 Phase 1/2 Clinical Trial:
In the Phase 1/2 clinical trial, EB-101 was administered to non-healing chronic wounds on each subject which were assessed for wound healing at predefined time points up to several years to date. The primary endpoints of the clinical trial assessed safety and evaluated wound healing after EB-101 administration compared to control untreated wounds. Secondary endpoints included expression of collagen C7 and restoration of anchoring fibrils at three and six months post-administration.
Clinical data were presented at the Society of Investigative Dermatology (SID) conference by Stanford collaborators, and demonstrated that EB-101 treated wounds were significantly healed >50% for more than two years post-administration. The data included:
Wound healing, defined as >50% closure after EB-101 administration, was observed in:
-- 100% (36/36 treated wounds, n=6 subjects) at 3 months;
-- 89% (32/36 treated wounds, n=6 subjects) at 6 months;
-- 83% (20/24 treated wounds, n=4 subjects) at 12 months;
-- 88% (21/24 treated wounds, n=4 subjects) at 24 months;
-- 100% (6/6 treated wounds, n=1 subject) at 36 months post-administration.
Collagen VII (C7) expression: C7 and morphologically normal NC2 reactive anchoring fibrils were observed in EB-101 treated wounds up to two years post-administration.
Importantly, data from a supportive natural history study of 1,436 wounds from 128 patients with RDEB, established by Stanford and EBCare Registry, were also presented at the conference and to the FDA. Notably, 13 RDEB patients with a total of 15 chronic wounds were treated with an allograft product, including Apligraf® and Dermagraft®. Of these wounds treated with allografts, only 7% (1/15 treated wounds) remained healed after 12 weeks, and 0% (0/15 treated wounds) remained healed after 24 weeks. This is a meaningful finding of the natural history study, as there are no approved therapies for RDEB patients that demonstrate significant wound closure after two months post-application.
About Epidermolysis Bullosa (EB) and Recessive Dystrophic Epidermolysis Bullosa (RDEB): EB is a group of devastating, life-threatening genetic skin disorders characterized by skin blisters and erosions all over the body. The most severe form, recessive dystrophic epidermolysis bullosa (RDEB), is characterized by chronic skin blistering, open and painful wounds, joint contractures, pseudosyndactyly and a shortened life span. Typically, wounds on patients with RDEB, also known as "butterfly skin" syndrome, can remain unhealed for months to years due to the inability of the skin to stay attached to the underlying dermis and can cover a large percentage of the body. Patients with RDEB lack functional type VII collagen owing to mutations in the gene COL7A1 that produces C7 collagen and is the main component of anchoring fibrils, the “velcro” that helps stabilize the skin on the basement membrane.
EB patients suffer through intense pain throughout their lives, with no effective treatments available to reduce the severity of their symptoms. Along with the life-threatening infectious complications associated with this disorder, many individuals often develop an aggressive form of squamous cell carcinoma (SCC).
About EB Research Partnership (EBRP): EBRP is the largest 501(c)(3) nonprofit dedicated to funding research aimed at treating and ultimately curing Epidermolysis Bullosa, a group of devastating and life-threatening skin disorders that affect children from birth. EBRP uses a sustainable philanthropic model via venture philanthropy for all of its research commitments. To learn more, please visit www.ebresearch.org.
About Abeona: Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene therapies for life-threatening rare genetic diseases. Abeona's lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). Abeona is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa (EB), ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. In addition, Abeona has a plasma-based protein therapy pipeline, including SDF Alpha™ (alpha-1 protease inhibitor) for inherited COPD, using its proprietary SDF™ (Salt Diafiltration) ethanol-free process. For more information, visit www.abeonatherapeutics.com.
Investor Contact:
Christine Silverstein
Vice President, Investor Relations
Abeona Therapeutics Inc.
+1 (212)-786-6212
csilverstein@abeonatherapeutics.com
Media Contact:
Andre’a Lucca
Vice President, Communications & Operations
Abeona Therapeutics Inc.
+1 (212)-786-6208
alucca@abeonatherapeutics.com
Abeona: Preparing For Liftoff - The Next AveXis?
SeekingAlpha.com
Feb 14, 2017
Summary
- On Thursday, February 16, Abeona will present initial data from its clinical trial investigating ABO-102 in Sanfilippo Type A at the WORLDSymposium.
- Clinical validation of a biotechnology company's technology is usually a defining moment in the company's evolution and a highly value-enhancing event for shareholders.
- Clinically validated gene therapy companies trade at around 7-11x the valuation of companies with technologies yet to be validated with human data.
- If successful, I don't see why Abeona won't trade at similar market caps to companies like AVXS and ONCE. Near-term price target is $30/share.
- Sophisticated biotech hedge funds have recently appeared on the shareholder register, insiders have been buying the stock, and a considerable number of call options traded last week.
Executive Summary and Investment Thesis
Abeona Therapeutics (NASDAQ:ABEO) is a biotechnology company with a number of early- and late-stage assets. This week the company will present initial data on its lead compound, ABO-102 for Sanfilippo syndrome at the WORLDSymposium (We're Organizing Research on Lysosomal Diseases) in San Diego (Feb. 13-17).
The validation of a biotechnology company's key technology is usually a defining moment in the evolution of that company and usually creates significant value for the company's shareholders. Like other gene therapy companies with unproven technology, Abeona trades at a substantial discount to those companies with validated technology, and I believe that validation of Abeona's lead technology could drive the company's share price toward $30/share, which would put its valuation in line with those companies that have validated technology - e.g., AveXis (NASDAQ:AVXS), Spark Therapeutics (NASDAQ:ONCE), and Ultragenyx Pharmaceutical (NASDAQ:RARE).
Longer term, I believe ABEO has the technologies that could be worth more than $100 per share, but the purpose of this report is to preview the imminent clinical catalyst, and readers should refer to previous work for the full company background and the longer-term investment thesis.
I note that a number of highly sophisticated biotech hedge funds have recently appeared on the shareholder register, there has been considerable insider buying over the past 18 months, and in recent weeks, a substantial number of March call options have traded.
As with all biotech investments, the outcome of an investment is very dependent on clinical trial outcomes, which is speculative, and the key company specific risk in Abeona is the failure to commercialize any of its clinical programs. Cash on balance sheet of $72m will provide support for the shares at $1.75 if clinical trials fail. That said, this company is investigating drugs for ultra-rare terminal diseases where there is currently no approved agent, and this means the hurdle for approval at the FDA is very low, and the clinical trial data to date is highly encouraging. With cash burn of about $1m per month, the company has over three years of cash burn on balance sheet, so there is no need for near-term funding.
extensive article continues;
https://seekingalpha.com/article/4045696-abeona-preparing-liftoff-next-avexis
Rare Diseases: Biotech's High Risk, Highest Reward Sub-Sector
Ken Kam, Contributor
Forbes.com
June 27, 2017
In How To Maximize Biotech Returns Under Donald Trump, Todd Hagopian highlighted Rare Diseases, a sub-sector that includes companies developing novel drugs for diseases that affect small patient populations. The often incredibly high price tags for some of these drugs has generated a whirlwind of negative publicity, creating what Todd Hagopian believes is biotech’s high risk, highest reward sub-sector.
Todd started his Biotech fund at Marketocracy in March, 2011. The fund has returned 28.59% since inception and outperformed every mutual fund manager in the country for the past 5 years. Before taking anyone’s investment advice, you should always check out their track record. Here is Todd’s.
Ken Kam: Todd, tell me why you are excited about the Rare Diseases sub-sector?
Todd Hagopian: It is a very risky, but extremely attractive sub-sector. I believe we will start to see fewer FDA restrictions, and faster, easier, cheaper FDA approvals, specifically for diseases that have no current cure. If the Trump administration takes these steps, the companies who already have a full portfolio of Rare Disease drug candidates in their pipeline will have the most to gain.
Kam: You mentioned that these stocks are risky, what is the biggest risk in this sub-sector?
Hagopian: Anytime you are trying to accomplish something that no other company has done, such as cure a rare disease, there is inherent risk. When you add the fact that many of these diseases only affect tens of thousands of people, the only way to make the math work, when coming out with a cure, is to have a very high price tag on the drug. In today’s legislative environment, I doubt that there will be action taken on controlling drug prices, but it will continue to be front and center in the news.
Kam: So, you don’t think the government will take action on drug prices?
Hagopian: I think there are other ways the government can lower the cost of care in the United States. If they go after the drug manufacturers, by limiting their earnings potential, the result will ultimately be less new drugs coming to the market, because the return on investment will be too small for the drug manufacturers to tackle the diseases which have no cures. I could see the government taking action against the pharmacy benefit managers, which play a role as the middlemen between the drug manufacturers, the pharmacies, and the insurance industry. This is a low-risk way for the government to take action without stifling innovation in areas of biotech where it is needed most.
Kam: What stock is your most aggressive pick in this sub-sector?
Hagopian: I have, just recently, made an investment into Abeona Therapeutics (ABEO). The company’s lead drug candidate (ABO-102) was recently granted Fast Track designation by the FDA, which will help them drive the drug to market quicker than the usual drug approval process. This is a gene therapy designed for Sanfilippo Syndrome Type A, which is a rare autosomal recessive disease, which affects all of the body’s cells and organs, and leads to premature death in children.
On top of this lead drug candidate, the company boasts an impressive pipeline of nine other drug candidates which range between preclinical and phase two trials, across four different areas of expertise (metabolic, dermatology, hematology, and plasma therapies). This is the exact type of company who would benefit most from an easing regulatory environment, because they are getting ready to launch into the trial phases, which are the long, expensive part of the process, which may get made easier with upcoming legislation. They already have the drugs researched, and ready to go, they would be among the first to drive their rare disease portfolio through a cheaper, faster process, if that is what is coming down the road from this administration.
Kam: Very interesting. How big of a stake did you take, and what is your price target?
Hagopian: I started with a 5% stake in my portfolio, because I believe the company is trading at a great value right now, but I won’t hesitate to raise that stake if I have the opportunity to buy on future dips in the stock price. While the stock is trading at less than $6, the analysts are expecting this company to reach $15, with even the lowest analyst estimate coming in at $11. I believe this stock will reach $18over the next 24 months, which would be a return of over 200%.
Kam: Those are pretty aggressive expectations, what is the biggest risk with ABEO?
Hagopian: With high rewards, there is always high risk. ABEO has never brought a drug to the market, they are trying to cure incurable diseases, they are dabbling in a lot of different areas, there is pricing legislation risk, and the easing of regulations may never come. All in all, this stock will not be for those who have weak stomachs. All that said, I believe that the company’s first drug will succeed, which will start to fund the rest of the pipeline, and this company could become the next BMRN over the long-term.
Kam: Why is now the right time to be investing in the rare disease sub-sector?
Hagopian: Let me be clear here, this should never be a sub-sector that you enter as your only biotech investment, it is far too risky. It should always be used as part of a broader biotech portfolio strategy. That said, if you want to outperform the broader biotech sector, this is a must-have sub-sector in your portfolio. It is also not a sub-sector where you want a whole bunch of small positions in many companies. There will be big winners, and big losers here. Do your research, find the high-potential future winners, or have someone do it for you, but don’t peanut butter spread your money in the rare diseases sub-sector, or you won’t get the high-reward benefit for the high-risk that you are taking on.
My Take: Biotech stocks are aggressive investments. As we have seen, time and time again, companies can swing 50% in a matter of months on drug trial successes/failures. Clinical-stage companies carry even more risk than traditional biotech companies.
It takes expertise and a lot of time to stay on top of clinical developments. This is why sector funds are a better way to play the biotech field for most investors.
Todd’s approach is to focus a portion of his portfolio on clinical stage biotechs, while balancing his portfolio with extreme value large caps within the industry, thus allowing him to participate in the upward trend without risking it all on a single stock.
Overall, Todd has a long track record of beating the experts, across different industries. For a full review of his 20+ articles on the market, please visit his profile. For information about investing with Todd, click here.
Abeona Therapeutics Receives FDA Orphan Drug Designation for ABO-201 Juvenile Batten Disease Gene Therapy Program
GlobeNewswire.com
Thu June 29, 2017 8:15 AM
NEW YORK and CLEVELAND, June 29, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced today that the FDA has granted Orphan Drug Designation (ODD) for Abeona’s ABO-201 program (AAV-CLN3), the AAV-based single intravenous gene therapy program for juvenile Batten disease, a fatal lysosomal storage disease of the nervous system caused by autosomal-recessive mutations in the CLN3 gene.
“Receiving FDA orphan drug designation for ABO-201 augments Abeona’s suite of regulatory achievements, providing certain benefits and incentives, including marketing exclusivity, that are strategically important from a regulatory and commercial perspective,” stated Timothy J. Miller, Ph.D., President & CEO of Abeona Therapeutics Inc. “The published ABO-201 preclinical data from Dr. Tammy Kielian’s lab support the clinical translation for patients with juvenile Batten disease, and demonstrated the importance of selecting the right vector and delivery route for potential CNS benefit and to remove the underlying pathology associated with the disease. This designation helps advance the ABO-201 program and we look forward to initiating human clinical trials later this year.”
Preclinical data supporting clinical trials for ABO-201 (AAV-CLN3), the AAV-based single intravenous gene therapy program for juvenile Batten disease, (juvenile neuronal ceroid lipofuscinosis, JNCL), were published in the September 2016 issue of the Journal of Neuroscience (doi: 10.1523/JNEUROSCI.1635-16.2016). The publication article can be accessed by clicking on the following link: http://www.jneurosci.org/content/36/37/9669.short.
About Orphan Drug Designation: Orphan drug designation is granted by the FDA to novel drugs or biologics that treat rare diseases or conditions affecting fewer than 200,000 patients in the U.S. The designation allows the drug developer to be eligible for a seven-year period of U.S. marketing exclusivity upon approval of the drug, as well as tax credits for clinical research costs, the ability to apply for annual grant funding, clinical trial design assistance, and the waiver of Prescription Drug User Fee Act (PDUFA) filing fees.
About ABO-201: ABO-201 (AAV CLN3) is an AAV-based gene therapy which has shown promising preclinical efficacy in delivery of a normal copy of the defective CLN3 gene to cells of the central nervous system with the aim of reversing the effects of the genetic errors that cause juvenile neuronal ceroid lipofuscinosis, also known as juvenile Batten disease (JBD). JBD is a rare, fatal, autosomal recessive (inherited) disorder of the nervous system that typically begins in children between 4 and 8 years of age. Often the first noticeable sign of JBD is vision impairment, which tends to progress rapidly and eventually results in blindness. As the disease progresses, children experience the loss of previously acquired skills (developmental regression). This progression usually begins with the loss of the ability to speak in complete sentences. Children then lose motor skills, such as the ability to walk or sit. They also develop movement abnormalities that include rigidity or stiffness, slow or diminished movements (hypokinesia), and stooped posture. Beginning in mid- to late-childhood, affected children may have recurrent seizures (epilepsy), heart problems, behavioral problems, and difficulty sleeping. Life expectancy is greatly reduced, and there are no approved treatments for JNCL.
About Abeona: Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene therapies for life-threatening rare genetic diseases. Abeona's lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). Abeona is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JBD), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa (EB), ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. In addition, Abeona has a plasma-based protein therapy pipeline, including SDF Alpha™ (alpha-1 protease inhibitor) for inherited COPD, using its proprietary SDF™ (Salt Diafiltration) ethanol-free process. For more information, visit www.abeonatherapeutics.com.
Investor Contact:
Christine Silverstein
Vice President, Investor Relations
Abeona Therapeutics Inc.
+1 (212)-786-6212
csilverstein@abeonatherapeutics.com
Media Contact:
Andre’a Lucca
Vice President, Communications & Operations
Abeona Therapeutics Inc.
+1 (212)-786-6208
alucca@abeonatherapeutics.com
6 million shares @ $7.00 is the offering
Isn't size and price of an offering a SEC requirement?
no i'm sitting with free shares...i'm good
I wouldnt say "no posts" ;)
I sold half also
Just sold half my position, sort of as a hedge. I feel like a pullback is coming but if not I still hold 3K shares.
She doesn't act as if she wants to stop.
Keep on keeping on.
Check out the article SeekingAlpha put out today 9/16/2016
$5 AH. Very nice.....
Great long term play here but 4.30 is good enough for me.
Still pretty low volume....seems under radar still to me!
It's noticed. It's just not being commented on......
took a little longer then I thought to get to 3.50, but it got there. Now should be support in that range.
still nobody like this play. Another long term winner here with lots of trading opportunities.
Nobody found you yet? Dont worry your time will come.
Lonely and forgotten for now.....dont worry nobody wants the 2s but they will love the 3s.
Will run big soon just needs to be found
Nobody seems to like this.....great time to buy! Putting this one in the IRA.
ABEO: Gene edit investors on ABEO today. 4/1/2016
Investors for the highly influential "WallStreetPit" are on ABEO as of a few hours ago.
These are the same folks that are sending the gene editing & CRSPR-9 stocks into orbit.
Those guys have major ability to move a good stock.
Abeona Therapeutics Secures Key Regulatory Approvals for Clinical Trials In Europe
http://marketexclusive.com/abeona-therapeutics-secures-key-regulatory-approvals-for-clinical-trials-in-europe/1309/
$ABEO recent news/filings
http://abeonatherapeutics.com/
bullish 4.47
basing and starting to make higher highs & higher lows
pullback in new uptrend
CMF green
bullish divergence
high volume spike with price gap up is support
double bottom
## source: finance.yahoo.com
Tue, 01 Dec 2015 21:17:49 GMT ~ ABEONA THERAPEUTICS INC. Files SEC form 8-K, Other Events
read full: http://biz.yahoo.com/e/151201/abeo8-k.html
*********************************************************
Tue, 01 Dec 2015 14:03:00 GMT ~ Abeona Therapeutics to Present at Piper Jaffray 27th Annual Healthcare Conference
[Marketwired] - Abeona Therapeutics, Inc. , a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today announced that Tim ...
read full: http://finance.yahoo.com/news/abeona-therapeutics-present-piper-jaffray-140300246.html
*********************************************************
Thu, 26 Nov 2015 11:10:13 GMT ~ Accuride Corporation (ACW): Are Hedge Funds Right About This Stock?
read full: http://www.insidermonkey.com/blog/accuride-corporation-acw-are-hedge-funds-right-about-this-stock-389543/
*********************************************************
Mon, 23 Nov 2015 13:05:00 GMT ~ Direction of Market Influences - Research on EVINE Live, hhgregg, Abeona Therapeutics and Edap Tms
[Accesswire] - NEW YORK, NY / ACCESSWIRE / November 23, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: EVINE Live ...
read full: http://finance.yahoo.com/news/direction-market-influences-research-evine-130500125.html
*********************************************************
Wed, 18 Nov 2015 14:03:00 GMT ~ Abeona Therapeutics to Present at Jefferies 2015 Global Healthcare Conference
[Marketwired] - Abeona Therapeutics, Inc. , a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today announced that Tim ...
read full: http://finance.yahoo.com/news/abeona-therapeutics-present-jefferies-2015-140300813.html
*********************************************************
$ABEO charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$ABEO company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/ABEO/company-info
Ticker: $ABEO
OTC Market Place: Not Available
CIK code: 0000318306
Company name: Abeona Therapeutics Inc.
Company website: http://abeonatherapeutics.com/
Incorporated In: DE, USA
Business Description: Access Pharmaceuticals, Inc. is an emerging pharmaceutical company focused on the development and commercialization of proprietary products for the treatment and supportive care of cancer patients. Access has one approved product, two products in Phase 2 development, and five preclinical development programs. The company's approved product is MuGard(TM) for the management of oral mucositis (a common and debilitating side effect of many cancer therapies) for which marketing authorization has been allowed by the FDA. Access' ProLindac(TM), a polymer-linked platinum cancer drug is in Phase 2 clinical testing in cancer patients, as is Phenylbutyrate, a pleotropic agent which current evidence suggests acts as both an HDAC inhibitor and a differentiating agent. The Company's preclinical development programs include Angiolix, a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is potentially targeted to a number of tumor types, including breast and ovarian; Prodrax, a non-toxic prodrug which is activated in the hypoxic zones of solid tumors to kill tumor cells; Alchemix, a chemotherapeutic agent that combines two modes of action to overcome drug resistance, and oral insulin, which utilizes the company's Cobalamin(TM) oral drug delivery technology.Less >>
$ABEO share structure
## source: otcmarkets.com
Market Value: $152,011,318 a/o Nov 30, 2015
Shares Outstanding: 32,690,606 a/o Aug 14, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.01
$ABEO extra dd links
Company name: Abeona Therapeutics Inc.
Company website: http://www.accesspharma.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/ABEO/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/ABEO/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=ABEO+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=ABEO+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=ABEO+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/ABEO/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/ABEO/news - http://finance.yahoo.com/q/h?s=ABEO+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/ABEO/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/ABEO/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/ABEO/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/ABEO/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/ABEO/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/ABEO/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/ABEO/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/ABEO/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=ABEO+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/ABEO
DTCC (dtcc.com): http://search2.dtcc.com/?q=Abeona+Therapeutics+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Abeona+Therapeutics+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Abeona+Therapeutics+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.accesspharma.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.accesspharma.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.accesspharma.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/ABEO/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/ABEO
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/ABEO/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/ABEO/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/ABEO/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000318306&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/ABEO/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/ABEO/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/ABEO/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/ABEO/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=ABEO&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=ABEO
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/ABEO/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=ABEO+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=ABEO+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=ABEO
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=ABEO
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=ABEO+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/ABEO/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=ABEO+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/ABEO.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=ABEO
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/ABEO/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/ABEO/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/ABEO/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/ABEO/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/ABEO
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/ABEO
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/ABEO:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=ABEO
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=ABEO
$ABEO DD Notes ~ http://www.ddnotesmaker.com/ABEO
me too, got 2.5 k at 4.15, just sold em......
I was able to get 3K @ $4.18 this am.......
The low volume dip pre-market made me scratch my head.
Looking good here, again!
ABEO stronger on news today. With some volume could run back up. Has been down for too long.
ABEO. Soros and another increasing stake. Bullish 9:04 am Abeona Therapeutics announces a direct placement of ~1.55 mln shares of registered common stock, at $5.50/share, with Soros Fund Management & Perceptive Life Science Fund groups (ABEO) : Co announced it had entered into a definitive purchase agreements with two healthcare institutional investors, Soros Fund Management and Perceptive Life Science Fund, and two Members of the Board of Directors, to raise $8.5 million in a direct placement of registered common stock.
The financing is comprised of 1,547,273 shares of common stock at a price of $5.50 per share.
Co plans to use the proceeds of the financing for the development of its proprietary rare disease programs, working capital and general corporate purposes.
ABEO. agree, but could be another two weeks away. Bought the dips and holding.
ABEO (formerly PTBI) High time George Soros increased his 5% stake. Looks to have bottomed, keeping on radar as of today.
$AEBO – nice close above the 200 DMA @ 6.06 – the 50 DMA @ 7.03 is the Key resistance level to close above & ............. -
ABEO....Moving right back up. Bit of a squeeze going on.....
My $8.00 per share I bought in at sure doesn't look so great anymore. I thought I bought in at a bargain yet today I could have bought in for low $5's. I sure hope there's a plan. Thought this stock was a $16.00 stock but for now we go down everyday, sad to see.
Followers
|
54
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1251
|
Created
|
02/13/07
|
Type
|
Free
|
Moderators |
Abeona Therapeutics Announces Fourth Quarter and Full Year 2015 Summary Financial Results and Recent Operational Highlights |
NEW YORK, NY and CLEVELAND, OH -- (Marketwired) -- 03/08/16 -- Abeona Therapeutics, Inc. (NASDAQ: ABEO), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today announced summary financial results for the fourth quarter and full fiscal year ended December 31, 2015. The Company will provide a business update for investors and other stakeholders on a conference call, Wednesday, March 9th, at 4:45 pm (Eastern). Tim Miller, Ph.D., President and CEO and Jeffrey Davis, Chief Operating Officer, together with other executives, will conduct the call. Interested parties are invited to participate in the call by dialing 877-269-7756 (toll free domestic) or 201-689-7817 (international). The call will consist of an overview of the Company's 4Q15 financials, and a discussion of business highlights. "The past year has led to significant advancements in our goal of building a leadership position in the field of gene therapy and plasma protein therapies towards transforming the lives of patients with rare diseases," stated Steven H. Rouhandeh, Executive Chairman. "In 2015, we expanded our pipeline with two clinical stage AAV gene therapies for Sanfilippo syndrome types A and B, added a third AAV gene therapy product in Juvenile Neuronal Ceroid Lipofuscinosis (JNCL) (also known as juvenile Batten disease), signed a license to an innovative CRISPR-Cas9 gene editing platform in rare blood disorders, with an initial focus in Fanconi anemia, strengthened our team, and added substantial financial resources to our balance sheet. In 2016, our priorities include driving our AAV gene therapy and alpha-1 protease inhibitor programs into the clinic, and advancing our gene editing programs including defining of regulatory pathways to bring our CRISPR product candidates to patients." Tim Miller, Ph.D., President and CEO, stated, "2016 will be an exciting, transformative year for Abeona Therapeutics as we position ourselves to enter multiple human clinical trials with our pipeline of innovative product candidates. As recently announced, the FDA allowance of the IND for the Phase 1/2 clinical study of ABO-102 for patients with Sanfilippo syndrome type A (MPS IIIA) moves our programs into the clinic here in the US, and we look forward to working with our collaborators to expand this program into Europe and Australia later this year. We believe that our gene therapy programs in Sanfilippo syndrome type B (ABO-101) and Juvenile Neuronal Ceroid Lipofuscinosis (ABO-201) will follow shortly. Lastly, we would like to thank our dedicated researchers and clinical collaborators, as well as the many dedicated patient foundations, for their tireless efforts and commitment to advancing new treatment options for these devastating unmet medical needs." Recent Abeona Highlights
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |